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Abstract  
Background 
The United Kingdom has committed to eliminating viral hepatitis as a public health threat. Innovative 
interventions for marginalised populations are required to realise this goal. In 2016, the HepCATT 
study team implemented a complex hepatitis C (HCV) intervention in three English drug treatment 
services, with five controls. We report qualitative study findings from two intervention sites to 
explore intervention success and transferability potential. 
Methods 
The intervention comprised multiple components, including a nurse facilitator, peer support and 
education initiatives. Qualitative data were generated at baseline (2014) and post-intervention 
(2016) at two sites through in-depth interviews, focus groups and observations. The 96 participants 
comprised drug service and intervention providers and clients with an injecting history. Data were 
triangulated and thematically analysed. 
Findings 
Client engagement with a HCV treatment service rose from 16 at baseline to 147 in 2016. There was 
no comparable increase at the five control sites. Baseline testing and treatment barriers included: 
limited HCV knowledge; fear of diagnosis and treatment; precarious living circumstances and service-
specific obstacles. Treatment engagement was aided by: intervention timeliness; improved 
communication structures; personalised care; streamlined testing and treatment pathways; peer 
support. 
Conclusion  
Multiple interrelated components influenced the increased levels of treatment engagement 
documented in HepCATT. The nurse facilitator, involved in implementation and innovation, was key 
to intervention success.  Baseline barriers correspond with international literature – indicating 
transferability potential. Control data indicate that biomedical innovation alone is not sufficient to 
increase engagement amongst the most marginalised. Sustainable resourcing of community services 
is crucial to effect change.  
 
Keywords: hepatitis C; intervention; treatment; people who inject drugs; qualitative 
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Introduction 
In 2016 the United Kingdom (UK), with 193 other countries, committed to eliminating viral hepatitis 
as a public health threat by 2030 [1]. This ambitious goal requires the development of innovative 
interventions targeted at marginalised populations. In the UK, as in other high income countries, over 
90% of incident hepatitis C virus (HCV) cases are among people who inject drugs (PWID) [2]. 
Modelling studies indicate that HCV treatment scale up among PWID reduces transmission 
opportunity, thus enabling elimination [3, 4]. HCV case finding in drug treatment services (DTS) is 
projected to be cost-effective, particularly when associated with increased treatment uptake [5]. 
New, highly tolerable and effective, direct-acting antiviral (DAA) treatments can capacitate 
community provision and treatment scale up – but not without attention to the manifold barriers 
faced by PWID in accessing care. 
 
HCV testing and treatment barriers for PWID have been extensively reported [6-10]. Some, such as 
interferon side-effect concerns, are likely to be ameliorated by increased access to and awareness of 
interferon-free DAA therapies. Other barriers are more intransigent. These include: injecting and 
HCV-related stigma; mistrust between PWID and health care providers; material deprivation and 
competing priorities; rigid tertiary care requirements and difficulties accessing and navigating care 
provided in hospital settings [6, 10]. HCV testing and treatment interventions in DTS are, however, 
not necessarily straightforward, particularly when associated with rigid and/or punitive opioid 
subsititution therapy (OST) provision [11]. Meaningful peer involvement can facilitate engagement 
[12-14], as can: HCV training for drug service providers; community nurse placements; contingency 
management; and dried blood spot (DBS) testing [12, 13, 15-17]. Qualitative studies [14, 18] suggest 
that cultural and management changes in DTS are also needed to support HCV case finding. These 
include: changing performance targets; reorientating workloads and prioritisation; reconfiguring 
client assessment forms and databases; enhancing community partnerships and involvement.  
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Together the evidence indicates that increasing HCV testing and treatment uptake among PWID 
requires a range of interventions. In the UK context, effective collaboration between the affected 
community and their organisations, local DTS, commissioners (responsible for planning and 
commissioning healthcare services in each locality), drug strategy teams and specialist hepatitis 
services is vital for intervention success. The HepCATT (Evaluation of interventions designed to 
increase diagnosis and treatment of patients with HCV infection in drug treatment settings) study 
team worked with these stakeholders to implement and evaluate a complex intervention, with the 
aim of informing best practice for HCV treatment engagement among PWID [19].  This paper reports 
findings from the qualitative study arm, which aimed to inform and assess the intervention.  
 
Methods 
The intervention  
The intervention was implemented in three DTS in different English cities. Sites were required to: 
represent rural and urban settings; have a client base of >200 PWID;  be reasonably intervention 
‘naïve’; and able to facilitate local HCV provider and commissioner support. Intervention components 
comprised: the appointment of a HCV nurse facilitator; a peer education and buddy system; HCV 
information resources and education initiatives; DBS testing; streamlining and integration of HCV and 
OST service provision; and liaison with stakeholders to agree HCV case finding and treatment targets. 
Five control sites were selected, according to the same size specification.  
 
A National HCV charity facilitated the peer and buddy system, demarcating distinct roles for each. 
Peers, required to have experience of living with HCV, were primarily responsible for providing 
education and training. Buddies, not required to have lived experience of HCV, took a supportive role 
- accompanying clients to hospital appointments, for example (for more detail see [21]).  
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The primary intervention outcome was ‘engagement with a HCV treatment service’. Engagement 
comprised: testing (HCV RNA, genotype, viral load); liver disease assessment and attendance at a 
consultation appointment. The outcome of engagement, rather than treatment uptake, reflects the 
uncertain UK treatment landscape at the time of the study, where DAA treatments were not 
available to all, with eligibility dependent on disease severity (people with cirrhosis given priority) 
and genotype. Quantitative baseline data for 2014 were collected retrospectively from the 
intervention and control sites. 
 
Intervention outcomes 
Across the three sites at baseline (2014) only 16 clients were engaged with a HCV treatment service. 
This increased to 147 in the intervention year (Table 1).  Equivalent data for the five control sites 
showed no evidence of any increase from baseline in rates of referral, attendance, engagement, or 
treatment. See [19] for details.  
 
Table 1. The HCV cascade of care at the 3 intervention sites  (see end of manuscript) 
 
The qualitative study  
The qualitative study was conducted pre- and post-intervention at two of the three intervention 
sites. Two sites (one rural, one urban) were chosen to aid project manageability with no qualitative 
data collected at the third site, where a change of drug service management necessitated a later 
intervention start date.  
 
Sample and data generation   
Data were generated between 2014 and 2016. Forty-eight PWID and 48 drug service and 
intervention providers (n=96) participated in 36 in-depth interviews and 11 focus groups pre and 
post-intervention (Table 2). DTS clients who currently or previously injected illicit drugs (‘PWID’) were 
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recruited through DTS staff and purposively sampled for variation in HCV testing and treatment 
history. The 48 PWID participants comprised 10 women and 38 men, with an age range of 19 – 69 
years old. Providers, comprising DTS staff (key workers, nurses, team leaders) and intervention 
implementers (NFs, peers and buddies), were recruited directly by the research team. Interviews 
lasted between 30-75 minutes, focus groups between 1-2.5 hours. All were conducted by OB in 
private rooms at the DTS.  
 
Table 2: Sample by data generation method (see end of manuscript) 
 
The pre-intervention client sample was divided into those who had previously tested positive for HCV 
but not entered treatment and those who had never had a test for HCV. Post-intervention, the client 
sample was divided into those who had ‘engaged’ with the intervention and those who had ‘not 
engaged’ (i.e. not been tested or attended a consultation at the treatment service). Fewer clients 
participated post-intervention, with ‘non-engagers’ difficult to recruit at both sites. 
 
The same topic guides were developed (by OB and MH) for both focus groups and interviews. At 
baseline, we aimed to: contextualise the pre-intervention setting; explore patient and provider 
intervention perceptions and needs; and unpack existing barriers and facilitators to HCV testing and 
treatment engagement. Baseline data analysis informed intervention design and implementation; 
also providing a comparator to assess intervention impact. Intervention topic guides, employed 6-8 
months after baseline, explored the perceived impact and efficacy of intervention components, with 
a focus on peer support acceptability and fit. Observations were made of the spatial layout of the 
DTS, and how HepCATT was advertised and given a physical presence within the sites. OB sat in on 
peer support drop-in sessions with clients, and observed interactions in canteen and waiting areas.  
Observations were recorded in field notes; uploaded to NVIVO 11 to supplement analysis. 
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Analysis  
We conducted a thematic analysis [20], with a coding framework incorporating both deductive (a 
priori) and inductive (data driven) codes. Data were analysed by the first two authors through 
triangulation using: (a) multiple methods (interviews, focus groups, observations); (b) multiple 
participant perspectives (service providers, clients); (c) multiple intervention sites; and (d) time 
points (pre/post intervention). The primary focus of triangulation was to identify congruence and 
divergence, including deviant cases for follow-up, and to maximise the confidence with which 
judgements were made. As part of this process, we presented findings to the wider HepCATT study 
team, including members of the Hepatitis C Trust and DTS staff. 
 
Ethics  
Ethical approval was obtained from the LSHTM Research Ethics Committee [8935] and the National 
Research Ethics Service [I5/EM/0062]. All participants read an Information Sheet and had 
opportunities to ask questions before providing written consent. Clients, peers and buddies received 
£15 in cash or vouchers for their time and expertise. 
 
Findings  
To contextualise and unpack the factors relating to intervention outcomes we first provide a 
summary of pre-intervention testing and treatment barriers, before addressing the post-intervention 
findings.  
 
Pre-intervention: testing and treatment barriers  
Pre-intervention, clients displayed variable HCV testing and treatment knowledge. Very few at either 
site were aware of what HCV testing entailed and the difference between detecting antibodies only 
and chronic infection through polymerase chain reaction (PCR) tests. Participants who had not been 
tested for HCV described: service obstacles, including perceived lack of testing availability;  
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perceptions of minimal HCV risk due to relatively safe injecting practices and/or lack of symptoms; 
confusion about the testing and treatment process; fear of a positive diagnosis and HCV stigma; 
concerns about interferon treatment; aversion to having a venous sample taken; and a desire to 
move away from a drug user identity: “It can make a person frustrated or angry if someone keeps 
asking them about hepatitis and you have left it [injecting drugs] behind … it doesn’t apply to me.” 
(Client, Untested, Site B) 
 
Untested clients, in particular, spoke of limited psycho-social ‘stability’. This was informed by 
multiple pressures, such as: substance dependence; temporary and inadequate housing; limited 
work options; comorbidities; difficult familial relationships; poverty; and engagement in illicit 
economies. While these pressures were differently configured and experienced, they often led to a 
deprioritisation of HCV: “I’ve got mental health issues as well. I was homeless and that is one of the 
reasons why I didn't get tested before I went into prison, because of the situation that I was in” 
(Client, Untested, Site A). Many clients experiencing precarity felt that testing could be additionally 
destabilising if it revealed them to be HCV positive: “What if it drives you back to the drugs?” (Client, 
Untested, Site A) 
 
Clients who had tested positive, but not recieved treatment, recounted perceptions of GPs’ lack of 
interest in them and HCV more generally. Additional treatment barriers comprised: competing 
priorities of substance dependence, comorbidities and housing instability; reluctance to commence 
interferon treatment and perceived unavailability of DAA treatments; perceptions of low treatment 
worth; abstinence requirements; lack of urgency related to felt wellness; lack of social support, 
physical immobility and problems accessing transport – often due to poverty: 
It’s [hospital] a long walk up the hill, maybe two miles to the top … A lot of our clients don’t have 
cars or transport or things like that, and they’re in ill health quite a lot of the time. (Keyworker 
Site A) 
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In addition, systemic problems of limited healthcare funding for HCV, few HCV specialist staff in 
treating hospitals, disjointed care provision between services, and perceptions of disciplinarian 
tactics used by hospitals, placed additional barriers on treatment uptake: “One strike and you’re out. 
It seems to be getting tighter and tighter” (Keyworker, Site A). 
 
Post-intervention: testing and treatment facilitators  
Multiple interrelated factors influenced the increased levels of treatment engagement documented 
in HepCATT. These included: intervention timeliness; personalised and flexible care; improved HCV 
communication structures; better HCV testing and treatment pathways, and the provision of a peer 
education and buddy support system. The latter has been addressed [21]; here, we report on the 
former four domains. 
 
Timeliness: capitalising on stability and new treatments 
For many clients, moments of psycho-social stability in their lives allowed them to entertain the 
prospect of getting HCV testing and/or treatment. For some, the intervention coincided with these 
moments, enabling engagement. Realising clients’ stability could be short-lived, nurse facilitators’ 
aimed for quick treatment assessment referrals – ideally within two-three weeks. In practice, 
referrals took longer – generally due to hospital-related factors such as lack of clinic capacity. In such 
situations, swift and clear communication to clients (and their key workers) reassured that the 
appointment was forthcoming. All clients during the intervention reported receiving letters when 
referred to the Site A HCV clinic: an improvement on the uneven communication reported pre-
intervention. 
 
The intervention co-incided with the growth in availability and use of DAAs in the UK; knowledge of 
new treatments was seen to influence clients’ engagement. Providers noted that positive feedback 
from clients who had undergone DAA treatment created a “ripple effect” among clients and staff. 
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DAA prioritisation restrictions could, however, cause tensions and falsely raise expectations. For this 
reason, some staff chose not to publicise new treatments: 
I'm not telling anyone at the moment [about DAAs] … otherwise they get their hopes up … if 
you're a [genotype] three you're having interferon so it’s a 50/50 chance so I’m better not 
saying anything to anybody.  (Nurse Facilitator, Site B) 
One Site B client was heartened by his perception that the nurse facilitator had “fought” to get him 
access to DAA treatment. He felt it was the right time to commence as he had ceased injecting and 
was reassured that DAA tolerability would allow him to continue working.  
 
Personalised and Flexible Care 
Nurse facilitators and key workers endevoured to ensure a person-centered approach to client care. 
Co-located at the DTS and hospital, nurse facilitatorss provided  a “familiar face” for clients at both 
sites. Clients, key workers and buddies remarked on the nurse facilitator’ss communication skills and 
the sense of care they brought to their interactions with clients. In Site B, the nurse facilitator sent 
clients text messages the day before their hospital appointments and actively tried to secure them 
access to DAA treatments. In Site A, the nurse facilitator made sure hospital appointment times 
corresponded with clients’ needs: “One gentleman had social anxiety, couldn’t manage to sit in a 
packed waiting room, so I gave him an appointment at ten to nine when it’s clear, he came in and the 
buddy sat outside” (Nurse Facilitator, Site A). 
 
Both nurses instigated a rapid, person-centred approach to test result delivery, proactively hunting out 
clients: “If it’s positive, I’ll make a plan to meet them … I’ll go out my way to find them” (Nurse 
Facilitator, Site B). From the clients’ perspective, this personalised approach was highly valued: 
She’s even phoned me up to say, listen, don’t forget, if you don’t want to go, let me know.  She’s 
good enough, she could have just sent me a letter out and just said, well, I sent him a letter, he 
never turned up. (Client, Engaged, Site B) 
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For clients testing positive who no longer came to the service, the Site B nurse facilitator contacted 
their GP to deliver the result. If the result was negative, she would update the client’s profile on the 
computer system and add a note to their key worker to inform the client. HCV treatment information 
was provided with testing results, with no pressure to commence. Both sites placed emphasis on on-
going engagement, with treatment as an open option. This was seen as vital for clients who 
traditionally might not be deemed eligible: 
Certainly we’ve had patients come to clinic who, on paper, you wouldn’t go there. You 
wouldn’t go there with interferon based treatments but for quite a few of them if there is 
the right support there and you build up that relationship … It is possible and I’m a strong 
advocate of that because I think at the moment people with mental health problems are 
likely widely excluded from treatment. (Nurse Facilitator, Site B) 
 
Pre-intervention, the detrimental impact of immediate hospital discharge for those who could not 
attend appointments was noted.  The Site A nurse facilitator personalised this interaction, with the 
aim of minimising client perceptions of judgement or exclusion:   
If we find out that they’ve not attended a clinic appointment and there’s a reason, like one 
girl broke a leg, then I’ll send a letter out and say ‘sorry, I heard about your broken leg, I have 
discharged you from the service. However, I’ve included a self-referral form. If you want to 
come back within the next six months fill it in and give it to your key worker’ so we’re not 
closing the door. (Nurse Facilitator, Site A) 
Key workers also endeavoured to personalise clients’ care throughout their HCV treatment journey; 
discussing testing and treatment options with them and sending text message reminders about 
hospital appointments with the option of peer support.  
 
HCV visibility and communication structures 
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Embedding HCV as a priority within the sites was an intervention imperative. To facilitate this, nurse 
facilitators fostered regular communication channels with key workers. At Site A, the nurse facilitator 
attended weekly team meetings to give feedback on client referrals and progress. She asked staff 
whether they had spoken to clients on a targeted list about their referral intentions and whether 
these prompts had helped. The Site B nurse facilitator provided key workers with HCV information 
and intervention updates, particularly regarding the progress of specific clients. Both sites arranged 
visits and talks from representatives of the Hepatitis C Trust, also a HCV consultant (Site A), to 
improve staff knowledge and aid HCV prioritisation.  
 
Key workers commented that one of the most beneficial aspects of HepCATT was being copied into 
correspondence between the hospital teams and clients. This allowed them to prepare their clients 
for appointments and make necessary arrangements to ensure attendance. Moreover, it gave them 
faith that the HCV referral process was working, which enhanced their willingness to support and 
promote HepCATT: “It [email communication from hospital] made you confident that it’s, the 
system’s going to work for a start, that we’re all communicating with each other” (Keyworker, Site A). 
At the same time, this process allowed the client to feel “valued” and know that they had a 
committed professional support network around them. 
 
At both sites, it was clearly communicated to clients who the nurse facilitator was, particularly at Site 
B, where she was more visible owing to her hands-on testing role and nurse uniform. The medical 
role and uniform was seen to have positive effect on client engagement by aiding legitimacy and 
credibility: 
I’ve had two clients who are now engaging in the actual treatment process, which, in all 
truth, if this project hadn’t have been, they wouldn't have took time out to engage in 
treatment and that. [As a key worker] you can talk till you’re blue in the face, but the fact 
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that a nurse is sat in front of them, in the nurse’s uniform, and giving them the advice and 
letting them know, that speaks volumes. (Keyworker, Site B) 
This excerpt also illustrates the value of an ‘outsider’ coming in to champion HCV; one who can 
circumvent entrenched,  potentially detrimental, key worker-client dynamics.  
 
Improved testing and treatment pathways 
Nurse facilitators were proactive in improving testing and treatment pathways, with different 
strategies aligned to site context. The Site B nurse facilitator had a clear directive to test and was 
strategic in targeting clients who came in to pick up their OST prescriptions. At Site A, key workers 
had been trained in DBS testing prior to the intervention; there was little need for the nurse 
facilitator to take this role. To counter this reduced opportunity to engage clients in treatment 
conversations she designed a self-referral procedure. Forms were placed on the reception counter 
next to a small post box, or available from key-workers. By self-referring, clients were able to 
discretely signal their ownership over the HCV treatment decision. This enabled GPs to be bypassed, 
giving clients a direct link to the treating hospital. It also served as a proxy to help to establish a 
relationship between the nurse, the key workers and the clients. For example, posters in consultation 
rooms advertising self-referral could prompt discussion between clients and key workers: 
Self-referral forms are meant for clients, but when they’re having their one-to-ones what 
could be easier as part of a motivational interview when somebody says ‘yeah, I’m going to 
look at my Hep C’ – there you go, fill it in. (Nurse Facilitator, Site A) 
 
The self-referral form played a role in reorienting decision-making with regard to determining a 
client’s readiness to test and treat, affecting pathways to engagement:  
“Key workers have come to me and said, ‘my client’s filled this [self-referral form] in and 
they’re not ready’ and [I would say], ‘yes, they clearly are ready.’ And I think it’s been 
accepted after that.” (Nurse Facilitator, Site A).  
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A similar negotiation took place at Site B, which the nurse facilitator sought to bypass by engaging 
clients directly: 
That’s why I go and get people myself because I make my own decision whether they’re 
suitable or not.  Not that I'm going against the key worker but they might not know or they 
may say, oh he doesn’t use needles.  Well yeah, might not use needles now but did he use 
needles 30 years ago?  Has he ever been tested before?  So I just prefer to go and ask them 
myself. (Nurse Facilitator, Site B) 
As a result of these initiatives, staff perceptions of client “readiness” to engage with HCV changed 
during the intervention, with more key workers willing to recommend that “chaotic” clients discuss 
their options with the nurse facilitator.  
 
Discussion 
Qualitative research is uniquely placed to explore community intervention needs and to unpack the 
local social and contextual factors shaping intervention delivery and impact. This is crucial to inform 
recommendations for implementation, scale up and transferability. Intervention results were 
impressive, showing a clear improvement in client engagement with treatment services. At baseline 
(2014), 16 clients were engaged with a treatment service across the three sites. This rose to 143 
clients in the intervention year (2016). At the two qualitative study sites engagement increased from 
13 at baseline to 123 in 2016. Without control data, much of this increase could be attibuted to 
changes in the HCV treatment landscape, such as increased availability and awareness of DAA 
treatments. Remarkably, given this “therapeutic revolution” [22], there was no increase in client 
engagement reported at the control sites from 2014 – 2016 [19]. The intervention figures delineate 
effacacy, but also illustrate that biomedical innovation alone is not sufficient to increase engagement 
amongst the most marginalised. Social-structural supports, resourced personel and changes to care 
pathways are crucial to effect change.  
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Participant reported testing and treatment barriers pre-intervention reflect those detailed in the 
qualitative literature. These include: limited HCV knowledge and testing confusion; perceptions of 
limited HCV risk or relevance; fear of HCV diagnosis and treatment; phlebotomy concerns; low 
treatment worth or ‘deservedness’; stigma and service access issues, often specific to tertiary care [7, 
14, 23-28].  Participants detailed multiple social and structural pressures which led to a de-
prioritisation of HCV, with concomitant fears that HCV diagnosis and/or treatment could precipitate 
additional social and psychological instability [14, 26, 28-30]. Structural and service specific barriers 
included an apparent lack of GP interest and accessibility, rigid hospital eligibility and appointment 
structures, and difficult access [27, 30, 31]. As previously argued [32, 33] the rationale for situating 
HCV interventions in community settings such as DTS is strong. The resonance of participant-
identified barriers at baseline with those documented in the international literature indicates 
potential for HepCATT intervention transferability and reach.   
 
This was a complex intervention with multiple components, including: educational support for clients 
and staff; strengthening of pathways between community and tertiary care; DBS testing; peer 
support; and integration of a nurse facilitator at each site. The nurse facilitator was an integral part 
of the intervention, and responsible for many of the intervention innovations. It is therefore difficult, 
and perhaps spurious, to try to tease out the differential impact of each component in isolation from 
the nurse facilitator. This dedicated placement worked in several ways to convey legitimacy and 
weight to HCV as a priority at the sites. Firstly, the part time placement illustrated a monetary 
investment in the DTS – practically and symbolically important in a period of increased disinvestment 
in and cutbacks to drug services in the UK. Secondly, the placement was associated with a 
Department of Health funded intervention and several notable University Institutions; the presence 
of research team members on site also requires note as a potential intervention impact [34]. Thirdly, 
the placement was an external and medical appointee. Although not specified in the job description, 
all three facilitator appointments were nurses. The nurse role was seen to provide legitimacy and 
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gravitas to HCV information provision, testing and referral, with an external placement obviating any 
counterproductive and entrenched client-staff dynamics.  
 
Dynamics circumvented by the external placement include those pertaining to HCV treatment worth 
and ‘readiness’. Client perceptions of low treatment ‘worth’ can unintentionally be reinforced by 
staff beliefs and messages regarding treatment ‘readiness’ [25]. Other innovations also ameliorated 
these dynamics. The self-referral system, for example, enabled client ownership of the referral 
process – signalling ‘readiness’ in those potentially deemed otherwise. This, in turn, helped shift key 
workers’ perceptions of their clients and the HCV treatment system. The self-referral system 
capitalised on the transience of client presence at the treatment centre and their self-identified 
windows of ‘stability’ and HCV interest. It circumvented the need for initial, possibily difficult, 
conversations about risk practices with providers. This intervention is highly transferrable across 
settings, but in order to be effective and ethical, it requires a strong and responsive pathway in place 
between self referral, testing, diagnosis, treatment referral and assessement opportunity.  
 
The HepCATT intervention did not incorporate HCV treatment provision at the DTS, as recommended 
to ameriorate barriers associated with tertiary care [16, 33, 35, 36]. In this respect the increase in 
treatment engagement is all the more remarkable – given that clients were required to attend at 
least one hospital appointment to fulfil engagement criteria. In order to aid hospital attendance the 
intervention implemented: peer ‘buddy’ support; correspondence with and appointment reminders 
through key workers; and visibility of the nurse facilitator at both the drug service and hospital sites, 
providing continuity of care and a ‘familiar face’ in what may have been otherwise perceived as a 
hostile environment. Client engagement is contextually dependent – variables such as hospital 
distance; availability of financial and practical support to attend appointments and hospital 
appointment waiting time will impact attendance [10]. Swift and supported testing pathways and 
referrals  in DTS can aid engagement, alongside peer and travel supports. Instutitional barriers, such 
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as immediate hospital discharge for non-attendance, may not always be amenable to intervention 
[31]. Notable, however, was the way in which swift and thoughtful communication from nurse 
facilitators to clients and key workers acted to tame and mitigate the damage associated with these 
barriers for clients.  
 
At both sites, the option for treatment was provided as an open door – something clients could come 
back to when it suited them and be personally assisted to obtain. It is important to acknowledge that 
the decision to undertake treatment will be informed by many factors, only some of which may be 
amenable to intervention. These include: patient priorities; co-morbidities; viral genotype; degree of 
underlying liver damage; potential duration of treatment; and how easy and acceptable HCV 
treatment is to access by people who are unstably housed or incarcerated. Attuned to the 
complexities of clients’ lives, the nurse facilitators created a space for engagement when clients were 
ready – importantly not withholding testing or HCV discussion due to perceived instability. 
Meaningful involvement of those ‘on the ground’ is crucial for intervention implementation and 
success. Elsewhere we detail the peer and buddy intervention components, along with the 
limitations of the intervention in fully supporting and integrating these at the sites [21]. Key worker 
involvement appeared better supported, with nurse facilitators proactively developing regular 
communication channels with key workers about the intervention and their clients’ progress. 
Opening up communication channels to include key workers is vital, with the HepCATT study 
illustrating the multiple benefits of including key workers in hospital-client correspondence.  
 
Uneven availability of DAA treatments, particularly to PWID, during the time of the intervention 
influenced the primary outcome measure of ‘engagement with a treatment service’ rather than 
‘treatment commencement’. This uncertainty was reflected in the reticence of nurse facilitators to 
publicise this treatment advance – with the ethical implications of inadvertently promoting curative 
but potentially unavailable treatments, a topic of debate among the qualitative team during the 
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intervention fieldwork. The ethics of an intervention of this kind, in a context of limited treatment 
access, is fundamental to consider. Also crucial is consideration of the ethics of interventions that 
enable needed resource in services – but only for the time period of the study. In order to gain and 
maintain community and provider trust it is necessary that interventions, such as HepCATT, can be 
sustainable. In a context of frequent retendering and budget restrictions in UK drug treatment 
services, dedicated resources may be required to enable PWID to fully benefit from the DAA 
treatment ‘revolution’.  
 
Conclusion 
In conclusion, multiple interrelated components influenced the increased levels of treatment 
engagement documented in HepCATT. Many were implemented and innovated by the nurse 
facilitator – this appointment was key to intervention success. Meaningful involvement of key 
workers in the testing and treatment pathways helped embed HCV as a priority at the DTS. Improved 
communication structures, along with a treatment self-referral system, operated to reconfigure staff 
perceptions of client ‘readiness’  for treatment – particularly those deemed ‘chaotic’. The uneven 
availability of DAA treatments at the time of the intervention informed the outcome measure of 
‘enagement’ and  highlighted the importance of reflecting on the ethical implications of intervention 
promise and sustainablity.   
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TABLES 
Table 1. The HCV cascade of care at the 3 intervention sites [19] 
 Site A Site B Site C 
 Baseline 
n (%) 
Intervention 
n (%) 
Baseline   
n (%) 
Intervention 
n (%) 
Baseline   
n (%) 
Intervention 
n (%) 
Hep C +ve PWID 87 100 173 236 30 62 
Referred 29 (33) 97 (97) 11 (6) 112 (47) 17 (57) 37 (60) 
Attended 15 (17) 67 (67)   3 (1)   68 (21) 5 (17) 24 (53) 
Engaged 10 (11) 55* (55)   3 (1)   68* (21) 3 (10) 20* (39) 
Treated   2 (2) 15 (15)   1 (0.6)   31 (13) 0 (0) 8 (13) 
 * Includes 3 (Site A), 2 (Site B) and 1 (Site C) clients discovered to be PCR negative 
 
Table 2: Sample by data generation method 
 Focus Groups (n) Interviews (n) Participants (n) 
Pre-
Intervention 
PWID  4 groups (n=26) 9 35 
Providers 2 groups (n=13) 9 22 
Post-
Intervention 
PWID  1 group (n=5) 8 13 
Providers 4 groups (n=16) 10 26 
TOTAL  11 groups (n=50) 36 96 *  
*includes 10 who took part in both pre- and post- intervention components  
 
